Alendronate binds to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This mechanism can be particularly beneficial for cancer patients who suffer from bone metastases, a condition where cancer cells spread to bone, leading to bone destruction and increased risk of fractures.
